FDA Approves Commercial GP2 Vials for Greenwich LifeSciences' FLAMINGO-01 Trial — Greenwich LifeSciences, Inc.

Event summary

FDA approved the first commercial lot of GP2 vials for use in Greenwich LifeSciences' Phase III FLAMINGO-01 trial.
The approval follows successful manufacturing and stability data submissions from three commercial lots produced in 2023–2024.
FLAMINGO-01 has screened over 1,000 patients, with the non-HLA-A*02 arm fully enrolled (250 patients).
Preliminary data shows an ~80% reduction in recurrence rates in the non-HLA-A*02 arm, aligning with Phase IIb results.

The big picture

Greenwich LifeSciences' FDA approval marks a critical de-risking step for its GLSI-100 immunotherapy, positioning the company to transition from late-stage trials to commercialization. The Phase III FLAMINGO-01 trial's preliminary data suggests potential for an 80% reduction in breast cancer recurrences, aligning with earlier studies and reinforcing the therapeutic's differentiated profile in a $4M+ global HER2-targeted market.

What we're watching

Regulatory Momentum: Whether the FDA approval accelerates BLA filing timelines and global regulatory submissions.
Clinical Efficacy: How preliminary recurrence rate data from FLAMINGO-01 compares to Phase IIb results as enrollment completes.
Manufacturing Readiness: The pace at which additional commercial GP2 lots are produced to support potential launch.